Compare Archer-Daniels-Midland Co (ADM) vs AstraZeneca plc (AZN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Archer-Daniels-Midland Co vs AstraZeneca plc — how do they compare? Archer-Daniels-Midland Co trades at $79.38 (market cap $38.78B), while AstraZeneca plc trades at $157.48 (market cap $248.14B). The key difference: AstraZeneca plc is far larger — about 6.4× Archer-Daniels-Midland Co's market cap, and Archer-Daniels-Midland Co pays the higher dividend (2.59%). Which is the better fit depends on your goals.
| ADM | AZN | |
|---|---|---|
Market Cap | $38.78B | $248.14B |
Sector | Consumer Staples | Health |
52-Week High | $87.32 | $209.48 |
52-Week Low | $56.00 | $147.06 |
Enterprise Value | $47.03B | $275.41B |
Dividend Yield | 2.59% | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADM trades at $80.49, up 5.09% on the day, with a bullish technical signal and strong earnings beats in recent quarters. Revenue has declined from $101.6B in 2022 to $80.3B in 2025, but net income margin improved to 2.16% in 2025. The company raised its 2026 outlook after Q2 results, citing biofuels and nutrition strength. Valuation ratios include a P/E of 21.98 and P/S of 0.48, indicating potential undervaluation relative to earnings growth prospects.
Outlook is positive with analyst consensus price target of $88.00, though execution risks and competitive pressures remain. Investment opportunity lies in continued margin expansion and biofuel demand, while risks include volatile commodity prices and debt levels. The stock offers a dividend yield supported by 379 consecutive quarterly payments.
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Archer-Daniels-Midland Co
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Read more on ADM →About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →
